Exhibit 99.1
3 May 2023
OKYO Pharma Limited
(“OKYO” or “Company”)
Result of General Meeting
The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that at the General Meeting (“GM”) of the Company held earlier today all resolutions were duly passed.
The result of the poll, including the proxy voting, is as follows:
| For | Against | Discretion | Withheld | For + discretion | ||||||||||||||||||||||||||||||||||||||
| Resolution | Description | Votes | % Votes Cast | Votes | % Votes Cast | Votes | % Votes Cast | Votes | Total Votes Cast (excl. Votes Withheld) | Votes | % Votes Cast | |||||||||||||||||||||||||||||||
| RES:001 | SHARE CONSOLIDATION | 545,538,277 | 99.93 | 375,103 | 0.07 | 32,915 | 0.006 | 60,371 | 545,946,295 | 545,571,192 | 99.93 | |||||||||||||||||||||||||||||||
| RES:002 | DIRECTORS TO ALLOT SHARES | 545,533,344 | 99.92 | 378,836 | 0.07 | 32,915 | 0.006 | 61,571 | 545,945,095 | 545,566,259 | 99.93 | |||||||||||||||||||||||||||||||
| RES:003 | PRE-EMPTION RIGHTS | 545,527,392 | 99.92 | 384,788 | 0.07 | 32,915 | 0.006 | 61,571 | 545,945,095 | 545,560,307 | 99.93 | |||||||||||||||||||||||||||||||
| RES:004 | AMENDMENT TO ARTICLES | 545,327,392 | 99.93 | 375,103 | 0.07 | 32,915 | 0.006 | 71,256 | 545,735,410 | 545,360,307 | 99.93 | |||||||||||||||||||||||||||||||
Further information on votes:
As at 2 May 2023, there were 1,658,792,349 ordinary shares in issue. Shareholders are entitled to one vote per ordinary share. Any vote withheld is not a vote in law and so has not been included in the calculation of the proportion of votes for and against any Resolution.
The resolutions were all passed on a poll, with votes cast in accordance with proxy voting instructions submitted to the Company by the relevant deadline, together with those cast at the GM itself, and will be available on the National Storage Mechanism, https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The result of poll and proxy voting will also be available on the Company’s website, www.okyopharma.com.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | +44 (0)20 7495 2379 |
| Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
| Optiva Securities Limited (Broker) | Robert Emmet | +44 (0)20 3981 4173 |